Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Share-based Compensation (2016 - 2025)

Conmed's Share-based Compensation history spans 16 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 20.48% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $28.3 million, up 10.72%, while the annual FY2025 figure was $28.3 million, 10.73% up from the prior year.
  • Share-based Compensation reached $4.9 million in Q4 2025 per CNMD's latest filing, up from $4.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.9 million in Q1 2025 to a low of $3.4 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $5.8 million, with a median of $5.8 million recorded in 2022.
  • The largest YoY upside for Share-based Compensation was 122.16% in 2025 against a maximum downside of 29.7% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $4.3 million in 2021, then surged by 33.98% to $5.8 million in 2022, then increased by 2.88% to $5.9 million in 2023, then rose by 5.05% to $6.2 million in 2024, then decreased by 20.48% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Share-based Compensation are $4.9 million (Q4 2025), $4.6 million (Q3 2025), and $4.9 million (Q2 2025).